This retrospective cohort compared metabolic and bariatric operations with incretin-based therapy, including GLP-1 receptor agonists. It used Epic Cosmos records on 107,280 adults aged 65 or over with type 2 diabetes and BMI 35 or more. Overlap weighting compared 2,843 operated and 104,437 drug-treated patients, giving most weight to those suited to either. Mean 1-year total weight loss was 23.0% after the operations and 6.87% with incretin-based therapy. Over 5 years, the operations were linked to lower mortality (HR .66), major cardiovascular events (HR .84), nephropathy (HR .73) and retinopathy (HR .65). The design is observational and far fewer patients were operated on, so unmeasured confounding may remain.
Why it is interesting: Long-term comparisons of bariatric operations and incretin-based drugs in older adults have been poorly defined. Here weight loss after the operations was more than three times greater, with fewer cardiometabolic complications and deaths.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.